000 02715cam a2200337 a 4500
003 EG-GiCUC
005 20250223032525.0
008 200220s2020 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.08.08.Ph.D.2020.Om.F
100 0 _aOmar Ali Abdalla Elkady
245 1 0 _aFormulation and characterization of promising carrier systems for pulmonary drug delivery /
_cOmar Ali Abdalla Elkady ; Supervised Hanan M. Ellaithy , Mina Ibrahim Tadros
246 1 5 _aصياغة وتوصيف أنظمة حمل واعدة لتوصيل العقار رئويا
260 _aCairo :
_bOmar Ali Abdalla Elkady ,
_c2020
300 _a131 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520 _aRisedronate sodium (RS) is a potent inhibitor of bone resorption; having an extreme poor permeability and limited oral bioavailability (0.62%). RS should be orally administered under fasting conditions, while keeping in an upright posture for at least 30 min, to diminish common gastroesophageal injuries. To surmount such limitations, novel Risedronate-chitosan (RS-CS) crosslinker-free nebulizable microspheres were developed adopting quality by design (QbD) approach and Risk assessment (RA) thinking. RS:CS ratio, surfactant (Pluronic® F127) concentration, homogenization duration, speed and temperature were identified using Ishikawa diagrams as the highest formulation- and process-risk factors affecting the critical quality attributes (CQAs); average particle size (PS) and entrapment efficiency (EE%). The risk factors were screened using Plackett-Burman design and the levels of the most significant factors were optimized using a multi-level factorial-design to explore the optimized system with the least PS, maximum EE% and a prolonged drug release profile. The optimized system (B6) was developed at RS:CS ratio of 1:7, a surfactant concentration of 2% (w/v) and a homogenization speed of 14000 rpm. It revealed well correlation with QbD theoretical prediction where, positively charged (47.9±3.39 mV) discrete, spherical microspheres (3.47±0.16 æm), having a high EE% (94.58±0.19%) and prolonged RS release over 12 hours (Q12h, 89.70±0.64%) were achieved
530 _aIssued also as CD
653 4 _aChitosan
653 4 _aCrosslinker-free
653 4 _aRisedronate sodium
700 0 _aHanan M. Ellaithy ,
_eSupervisor
700 0 _aMina Ibrahim Tadros ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aAsmaa
_eCataloger
905 _aNazla
_eRevisor
942 _2ddc
_cTH
999 _c76716
_d76716